AP2739A - Azaindazole compounds as CCRI receptor antagonists - Google Patents

Azaindazole compounds as CCRI receptor antagonists

Info

Publication number
AP2739A
AP2739A AP2011005685A AP2011005685A AP2739A AP 2739 A AP2739 A AP 2739A AP 2011005685 A AP2011005685 A AP 2011005685A AP 2011005685 A AP2011005685 A AP 2011005685A AP 2739 A AP2739 A AP 2739A
Authority
AP
ARIPO
Prior art keywords
receptor antagonists
azaindazole compounds
ccri
ccri receptor
azaindazole
Prior art date
Application number
AP2011005685A
Other languages
English (en)
Other versions
AP2011005685A0 (en
Inventor
Brian Nicholas Cook
Darren Disalvo
Daniel Robert Fandrick
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2011005685A0 publication Critical patent/AP2011005685A0/xx
Application granted granted Critical
Publication of AP2739A publication Critical patent/AP2739A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2011005685A 2008-09-26 2009-09-22 Azaindazole compounds as CCRI receptor antagonists AP2739A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26
PCT/US2009/057778 WO2010036632A1 (en) 2008-09-26 2009-09-22 Azaindazole compounds as ccr1 receptor antagonists

Publications (2)

Publication Number Publication Date
AP2011005685A0 AP2011005685A0 (en) 2011-04-30
AP2739A true AP2739A (en) 2013-09-30

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005685A AP2739A (en) 2008-09-26 2009-09-22 Azaindazole compounds as CCRI receptor antagonists

Country Status (24)

Country Link
US (4) US7879873B2 (es)
EP (1) EP2346868B1 (es)
JP (1) JP5507567B2 (es)
KR (1) KR20110060904A (es)
CN (1) CN102227425A (es)
AP (1) AP2739A (es)
AR (1) AR073689A1 (es)
AU (1) AU2009296839A1 (es)
BR (1) BRPI0919844A2 (es)
CA (1) CA2737472A1 (es)
CL (1) CL2011000668A1 (es)
CO (1) CO6351735A2 (es)
EA (1) EA201100524A1 (es)
EC (1) ECSP11010932A (es)
IL (1) IL210857A0 (es)
MA (1) MA32655B1 (es)
MX (1) MX2011002951A (es)
NZ (1) NZ591115A (es)
PE (1) PE20110854A1 (es)
TW (1) TW201018683A (es)
UA (1) UA103634C2 (es)
UY (1) UY32140A (es)
WO (1) WO2010036632A1 (es)
ZA (1) ZA201100625B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
PE20121433A1 (es) 2009-10-21 2012-11-10 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
MX2012006524A (es) * 2009-12-08 2012-07-17 Boehringer Ingelheim Int Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
WO2011137109A1 (en) * 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
AU2011295725B2 (en) 2010-09-03 2015-03-26 Forma Tm, Llc. Novel compounds and compositions for the inhibition of NAMPT
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
WO2013062945A1 (en) * 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
ES2620612T3 (es) * 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
LT3131902T (lt) 2014-04-14 2019-09-25 Boehringer Ingelheim International Gmbh Junginiai, kaip ror-gama moduliatoriai
AU2016342310B2 (en) 2015-10-23 2020-08-27 Vifor (International) Ag Novel ferroportin inhibitors
WO2017081310A1 (en) 2015-11-13 2017-05-18 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US20180354921A1 (en) 2015-11-13 2018-12-13 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
AU2017229128B2 (en) 2016-03-07 2022-04-07 Janssen Pharmaceutica Nv Antibacterial compounds and uses thereof
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TWI853814B (zh) * 2018-05-31 2024-09-01 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (en) * 2020-06-24 2021-12-30 Oregon Health & Science University Novel molecule for modulation of innate immune responses controlled by sting protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105853A1 (en) * 2002-06-12 2003-12-24 Chemocentryx, Inc. 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
WO2007002293A2 (en) * 2005-06-22 2007-01-04 Chemocentryx, Inc. Azaindazole compounds and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
AU658194B2 (en) 1991-03-28 1995-04-06 Eisai Co. Ltd. Heterocyclic-cyclic amine derivatives
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2116863A1 (en) 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
KR950702555A (ko) 1993-06-25 1995-07-29 모치츠키 노부히코 인다졸술포닐요소 유도체, 그의 용도 및 제조 중간체(indazolesulfonylurea derivative, its use and intermediate for its production)
CA2207201A1 (en) 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
JP2000501105A (ja) 1995-12-22 2000-02-02 デュポン ファーマシューティカルズ カンパニー 新規なインテグリン受容体アンタゴニスト
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
US6716978B2 (en) 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
AU5895500A (en) 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
DE60235114D1 (de) 2001-11-01 2010-03-04 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
AU2002357312A1 (en) * 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
DE60332717D1 (de) 2002-04-11 2010-07-08 Boehringer Ingelheim Pharma Heterocyclische amid-derivate als cytokin-inhibitoren
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
WO2006091496A2 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
BRPI0615048A2 (pt) 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
WO2007102883A2 (en) 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
JP2009544616A (ja) 2006-07-21 2009-12-17 武田薬品工業株式会社 アミド化合物
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
AU2008273017C1 (en) * 2007-06-29 2014-02-13 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as Raf kinase inhibitors
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (en) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
PE20121433A1 (es) 2009-10-21 2012-11-10 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
MX2012006524A (es) 2009-12-08 2012-07-17 Boehringer Ingelheim Int Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105853A1 (en) * 2002-06-12 2003-12-24 Chemocentryx, Inc. 1-aryl-4-substituted piperazines derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
WO2007002293A2 (en) * 2005-06-22 2007-01-04 Chemocentryx, Inc. Azaindazole compounds and methods of use

Also Published As

Publication number Publication date
US8338610B2 (en) 2012-12-25
IL210857A0 (en) 2011-04-28
CN102227425A (zh) 2011-10-26
CA2737472A1 (en) 2010-04-01
JP2012503664A (ja) 2012-02-09
CO6351735A2 (es) 2011-12-20
US8063065B2 (en) 2011-11-22
UY32140A (es) 2010-04-30
US20100093724A1 (en) 2010-04-15
EA201100524A1 (ru) 2011-10-31
UA103634C2 (en) 2013-11-11
WO2010036632A1 (en) 2010-04-01
EP2346868B1 (en) 2016-01-27
MX2011002951A (es) 2011-04-26
MA32655B1 (fr) 2011-09-01
US7879873B2 (en) 2011-02-01
CL2011000668A1 (es) 2011-10-28
AU2009296839A1 (en) 2010-04-01
AP2011005685A0 (en) 2011-04-30
PE20110854A1 (es) 2011-12-23
TW201018683A (en) 2010-05-16
NZ591115A (en) 2012-10-26
JP5507567B2 (ja) 2014-05-28
BRPI0919844A2 (pt) 2019-09-24
AR073689A1 (es) 2010-11-24
US20110086846A1 (en) 2011-04-14
KR20110060904A (ko) 2011-06-08
US20120136158A1 (en) 2012-05-31
US8163918B2 (en) 2012-04-24
ZA201100625B (en) 2011-09-28
ECSP11010932A (es) 2011-04-29
EP2346868A1 (en) 2011-07-27
US20120035370A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
IL212551A0 (en) Cxcr4 receptor compounds
IL212550A0 (en) Apj receptor compounds
EP2927224B8 (en) Receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
ZA201203452B (en) Cgrp receptor antagonists
ZA201202967B (en) Spiropiperidine compounds as orl-1 receptor antagonists
SI2501704T1 (sl) Spojine spiropiperidina kot antagonisti oral-1 receptorja
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
ZA201006830B (en) Heterocyclic compounds as adenosine receptor antagonist
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
PT2799428T (pt) Antagonistas de glicagina
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
ZA201005341B (en) Methods for inhibiting angiogenesis using egfl8 antagonists
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
ZA201301561B (en) 5-ht2b receptor antagonists
IL210927A0 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
GB0922304D0 (en) Radioiodinated compounds
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
ZA200906393B (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
GB0922455D0 (en) Ep2 receptor antagonists
GB0701632D0 (en) MET receptor antagonists
GB0901836D0 (en) EP4 receptor antagonists